Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report)’s share price hit a new 52-week high during trading on Monday. The company traded as high as C$18.35 and last traded at C$18.35, with a volume of 591 shares traded. The stock had previously closed at C$16.56.
Fennec Pharmaceuticals Price Performance
The stock has a market cap of C$646.20 million, a PE ratio of -152.92 and a beta of 3.90. The stock’s fifty day moving average is C$14.97 and its 200-day moving average is C$13.02.
Insider Buying and Selling
In related news, insider Robert Christopher Andrade sold 106,844 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of C$16.63, for a total value of C$1,776,815.72. Following the completion of the transaction, the insider directly owned 217,675 shares in the company, valued at approximately C$3,619,935.25. This represents a 32.92% decrease in their ownership of the stock. Also, insider Pierre Sayad sold 12,000 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of C$17.18, for a total value of C$206,160.00. Following the transaction, the insider owned 9,519 shares of the company’s stock, valued at approximately C$163,536.42. This represents a 55.76% decrease in their ownership of the stock. Corporate insiders own 16.20% of the company’s stock.
Institutional Trading of Fennec Pharmaceuticals
An institutional investor recently bought a new position in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. bought a new position in shares of Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned 0.30% of Fennec Pharmaceuticals as of its most recent SEC filing. 16.94% of the stock is owned by institutional investors.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
Read More
- Five stocks we like better than Fennec Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
